Skip to main content

Synaptogenix, Inc. (SNPX)

NASDAQ: SNPX · Delayed Price · USD
9.81
-0.06 (-0.61%)
After-hours:Oct 22, 2021 5:34 PM EDT
9.87
-0.48 (-4.64%)
At close: Oct 22, 4:00 PM
Market Cap61.16M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out3.97M
EPS (ttm)-6.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume225,104
Open10.31
Previous Close10.35
Day's Range9.75 - 10.35
52-Week Range6.25 - 14.50
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About SNPX

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior Uni...

IndustryBiotechnology
Founded2012
Employees4
Stock ExchangeNASDAQ
Ticker SymbolSNPX
Full Company Profile

Financial Performance

Financial Statements

News

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Image by Gerd Altmann from Pixabay  How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds.

2 weeks ago - Benzinga

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it ...

1 month ago - PRNewsWire

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, ...

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that...

2 months ago - PRNewsWire

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Inc (NASDAQ: SNPX) stock is plunging on heavy volume in reaction to the release of additional analyses of its Alzheimer's candidate bryostatin, showing that it missed primary endpoints. The...

2 months ago - Benzinga

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Associati...

NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its ...

2 months ago - PRNewsWire

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

NEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it w...

3 months ago - PRNewsWire

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restore...

NEW YORK, July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its ...

3 months ago - PRNewsWire

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

NEW YORK, July 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that a new...

3 months ago - PRNewsWire

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

NEW YORK, June 24, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. ...

3 months ago - PRNewsWire

Synaptogenix Announces $12.5 Million Private Placement

NEW YORK, June 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it h...

4 months ago - PRNewsWire

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD). To dat...

4 months ago - Benzinga

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update ...

4 months ago - PRNewsWire

Synaptogenix Responds to FDA Approval of Aducanumab

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement f...

4 months ago - PRNewsWire

Synaptogenix Announces Approval for Nasdaq Stock Market Listing

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced today that it has b...

4 months ago - PRNewsWire

Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market

NEW YORK, May 19, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that the Company's ...

5 months ago - PRNewsWire

Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum

NEW YORK, April 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative dis...

5 months ago - PRNewsWire

Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update

NEW YORK, April 1, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on...

6 months ago - PRNewsWire

Synaptogenix to Present at Upcoming Scientific Industry Conferences

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will...

7 months ago - PRNewsWire

Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Ala...

8 months ago - PRNewsWire

Synaptogenix Announces $14.0 Million Private Placement

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (the "Company" or Synaptogenix) (OTCQX: SNPX), formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securi...

9 months ago - PRNewsWire